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Letters to the Editor 283Successful treatment of disseminated methicil-
lin-resistant Staphylococcus aureus with fosfo-
mycin, cefoperazone/sulbactam and rifampin
followed by fusidic acid and rifampin
Few data exist regarding treatment of disseminated methi-
cillin-resistant Staphylococcus aureus (MRSA) with fosfomy-
cin and fusidic acid.1,2 We report the case of an MRSA-
associated catheter-related bloodstream infection (CR-BSI)
successfully treated with the combination of fosfomycin,
cefoperazone/sulbactam and rifampin followed by fusidic
acid and rifampin.
A 64 year-old Thai man with type II diabetes, chronic
renal failure, idiopathic thrombocytopenic purpura (ITP),
and prior anaphylaxis to vancomycin was admitted to
Thammasart University Hospital with fever and five days
of left knee and right ankle swelling. Two months prior to
admission, he underwent subclavian tunneled catheter
placement for hemodialysis. On admission, examination
revealed a temperature of 38.7 8C, pulse 110/minute,
respirations 18/minute, blood pressure 110/70 mmHg, with
swelling, erythema, and tenderness of the left knee and
right ankle. The leukocyte count was 19.1  109/L (94%
neutrophils), platelet count 70  109/L, blood urea nitro-
gen 55 mg/dL, serum creatinine 3.6 mg/dL; an HIV anti-
body test was negative and chest X-ray was normal. Blood
cultures were obtained from the tunneled catheter and
two peripheral sites. Given thrombocytopenia and prior
anaphylaxis to vancomycin, we initially treated with fos-
fomycin, rifampin and cefoperazone/sulbactam, catheter
removal, and drainage of the left knee and right ankle.
Four days into therapy, the blood and intraoperative
cultures grew MRSA susceptible to vancomycin, fosfomy-
cin, linezolid, fusidic acid, and rifampin and a transeso-
phageal echocardiogram revealed no evidence of valvular
vegetation. Susceptibility testing for fosfomycin was
performed using agar dilution, as recommended by the
manufacturer; a MIC of 128 mg/L characterizes a
strain as resistant, 32—64 mg/L as intermediate, and
16 mg/L as susceptible.3,4 After surgical debridement,
the patient received a two-week course of fosfomycin,
cefoperazone/sulbactam plus rifampin, followed by fusidic
acid plus rifampin for another 90 days. Post-treatment
surveillance blood cultures were negative and three
months post-treatment the patient had full resolution of
infection.
Successful treatment of severe MRSA can usually be
achieved with vancomycin or linezolid with or without
adjuvant oral therapies. In patients with MRSA infection
who are allergic to these medications or have thrombocy-
topenia, the combination of fosfomycin plus beta-lactam
and/or rifampin, followed by fusidic acid plus rifampin is
an attractive alternative. Fosfomycin is a phosphoenolpyr-
uvate analogue that irreversibly inhibits enolpyruvate
transferase resulting in prevention of the formation of
N-acetyl-muramic acid, the first stage of peptidoglycan
synthesis of the bacterial cell wall.3,5 It is bactericidal
with efficacy for MRSA, intermediate glycopeptide-suscep-
tible or -resistant enterococci, and Enterobacteriaciae.3,5In vitro data suggest a synergistic effect of fosfomycin and
fusidic acid in combination with beta-lactam and/or rifam-
pin.3 The rationale for these combination therapies are:
(1) to extend the antimicrobial spectrum of each agent
from that shown when used alone, (2) to potentiate the
antibacterial activities of the component agents, (3) to
decrease or to prevent the emergence of drug-resistant
bacteria, and (4) to reduce potential side-effects of the
drugs used.6,7 Although cefoperazone/sulbactam has lim-
ited in vitro activity against MRSA, early in vitro data
suggest its combination with fosfomycin is synergistic
against MRSA.6 Our report can be added to the short list
of successful treatment regimens against MRSA infection
using fosfomycin with beta-lactam and/or rifampin fol-
lowed by fusidic acid and/or rifampin.1 Furthermore,
our case is the first report of successful treatment of
severe disseminated MRSA infection with the combination
of fosfomycin with cefoperazone/sulbactam and rifampin
followed by fusidic acid and rifampin, as has been sup-
ported by evidence from in vitro studies.3,6
With the emergence of community-associated MRSA and
MRSA with reduced susceptibility to vancomycin, physicians
should be aware of alternative treatment strategies espe-
cially in patients for whom oxazolidinones and glycopeptides
cannot be used. While fusidic acid has not undergone reg-
ulatory approval for use in the USA, this regimen is a ther-
apeutic option in Europe, Australia, and most developing
countries.5 Our case supports the benefit of fosfomycin and
fusidic acid, in combination with beta-lactam and/or rifam-
pin for treatment of disseminated MRSA infection, and high-
lights the need for further studies of these combination
regimens.
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doi:10.1016/j.ijid.2006.05.004Rapid diagnosis of pneumococcal pneumonia in
adults using the Binax NOW Streptococcus
pneumoniae urinary antigen test
Streptococcus pneumoniae is the leading cause of commu-
nity-acquired pneumonia (CAP) worldwide and a major cause
of morbidity and mortality.1 S. pneumoniae is probably also
the leading cause of pneumonia of unknown etiology. The role
of microbiological tests is in the detection of an etiologic
agent causing infection so that directed therapy is possible.
However, the diagnosis of pneumococcal infections relies
heavily on culture of S. pneumoniae from blood or other
normally sterile fluids and is limited by prior administration
of antibiotics.2 For these reasons, causative pathogens may
remain unidentified in up to 50% of patients and broad-
spectrum antibiotic therapy may be continued unnecessarily
for prolonged periods of time.
The recent study by Genne et al. has shown that detection
of urinary pneumococcal antigen by using the Binax NOW S.
pneumoniae antigen test (immunochromatographic test
(ICT)) is a useful technique for the rapid diagnosis of pneu-
mococcal infections in adults.3 We performed a retrospective
study to investigate the performance of the ICT by use of
selected non-concentrated urine samples from adult CAP
patients. Approval to conduct the study was obtained from
the St Elisabeth Hospital Ethics Committee.
The CAP patients were included in the study only if a urine
sample was obtained within 48 h after hospital admission. The
cases were adult patients (>16 years of age) fromwhom blood
cultures grew S. pneumoniae (n = 52), or patients for whom
pneumococcal pneumoniawas confirmedwith positive sputum
culture results (n = 6). Controls (n = 136) were selected from
adult patients presenting with lower respiratory tract infec-
tions. A large proportion of the urine samples were obtained
from patients with proven legionnaires’ disease (n = 98)
according to criteria used by the European Working Group
on Legionella Infections (EWGLI; www.ewgli.org). The labora-
tory results of the remaining control patients were as follows:
Haemophilus influenzae (n = 10), Moraxella catarrhalis
(n = 3), Staphylococcus aureus (n = 4), Escherichia coli
(n = 2), Acinetobacter baumannii (n = 1), Streptococcus pyo-
genes (n = 2), Klebsiella pneumoniae (n = 1), Mycobacterium
tuberculosis (n = 3), Pneumocystis jirovecii (n = 1). Eleven
patients were included who had a four-fold rise or more in
complement-fixating antibodies against influenza A virus
(n = 2), adenovirus (n = 1), Chlamydia psittaci (n = 3), Myco-
plasma pneumoniae (n = 4), and parainfluenza virus (n = 1).Fifty-eight cases (median age 55 years; range 16—85 years)
and 136 controls (median age 56 years; range 16—84 years)
were included. Pneumococcal urinary antigen was positive
(after 15minutes reading) in 40 of 58 pneumococcal cases and
in three of 136 controls, giving a test sensitivity of 69% (95% CI
58—78%) and a test specificity of 98% (95% CI 93—99%) overall.
The frequencyofantigendetectionwasgreater forbacteremic
pneumococcal pneumonia (38/52 (73%)) than for non-bactere-
mic pneumococcal pneumonia (2/6 (33%)) (p = 0.07).
Of the three false-positive results in our study, two
occurred in patients who might be considered at high risk
for pneumococcal infection. One patient was a 78-year old
female admitted to the hospital with renal impairment,
malaise, fever, and shortness of breath. Chest radiography
showed extensive bilateral consolidation of the lung. Blood
cultures remained negative and in a sputum sample Haemo-
philus influenzae was cultured. She died a week after admis-
sion to the hospital. The second patient was a 31-year old HIV
positive female admitted with a respiratory tract infection
and a consolidation on chest radiograph. Blood and sputum
cultures were obtained but remained negative. Her condition
improved after initiation of amoxicillin therapy (1000 mg iv
per 6 hours) and she later showed a four-fold rise in comple-
ment-fixating antibodies against influenza A virus. The third
patient was a 42-year old female admitted with an acute
exacerbation of chronic pulmonary disease and blood cul-
tures yielding Haemophilus influenzae. None of these
patients had nasopharyngeal swabs taken to detect pneumo-
coccal carriage. It is possible that these patients had co-
infection with S. pneumoniae.
Although selection bias may possibly have affected our
sensitivity and specificity results, our findings indicate that
the sensitivity of the test is about 75% when positive blood
cultures are used as the ‘gold standard’. These findings are
similar to those of other investigators who have used the NOW
S. pneumoniae urinary antigen test. Murdoch et al. studied
420 adults with CAP, including 20 patients with pneumococcal
bacteremia, 16 (80%) of whom had detectable urinary anti-
gen levels.4 In determining the test specificity, Murdoch et al.
used 169 adult control patients with an admission diagnosis
other than a respiratory or infectious disease and found that
none had detectable pneumococcal antigen (specificity
100%). Dominguez et al. detected pneumococcal antigen in
urine specimens of 82% of 28 patients with bacteremic
pneumococcal pneumonia.5 The study by Dominguez et al.
also used control patients with pneumonia or bacteremia due
to other organisms and reported a test specificity of 97% (2/
71 tests positive). In the study by Genne et al., 67 adults with
